Brainstem Glioma in Adults
暂无分享,去创建一个
[1] D. Reardon,et al. Adult brainstem gliomas , 2016, Cancer.
[2] Shawn M. Gillespie,et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas , 2015, Nature.
[3] Ranadip Pal,et al. Erratum: Functionally defined therapeutic targets in diffuse intrinsic pontine glioma , 2015, Nature Medicine.
[4] M. Couce,et al. Histologically Proven Radiation‐Induced Brainstem Glioma 93 Months After External Beam Radiotherapy for Pituitary Macroadenoma: Radiation Treatment Dose and Volume Correlation , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[5] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[6] K. Aldape,et al. Adult brainstem gliomas: Correlation of clinical and molecular features , 2015, Journal of the Neurological Sciences.
[7] Nicholas J. Wang,et al. Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma , 2015, Nature Medicine.
[8] M. Remke,et al. An epigenetic therapy for diffuse intrinsic pontine gliomas , 2014, Nature Medicine.
[9] C. James,et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma , 2014, Nature Medicine.
[10] N. Martin-Duverneuil,et al. Temozolomide after radiotherapy in recurrent “low grade” diffuse brainstem glioma in adults , 2014, Journal of Neuro-Oncology.
[11] R. McLendon,et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas , 2014, Nature Genetics.
[12] M. Prados,et al. A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report. , 2014 .
[13] R. McLendon,et al. Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors , 2014, Journal of Neuro-Oncology.
[14] Amar Gajjar,et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.
[15] Stephen Yip,et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma , 2014, Nature Genetics.
[16] Michael Brudno,et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations , 2014, Nature Genetics.
[17] R. McLendon,et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. , 2014, Neuro-oncology.
[18] P. Kearns,et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy – Results of a United Kingdom phase II trial (CNS 2007 04)☆ , 2013, European journal of cancer.
[19] S. Muzumder,et al. Re-irradiation with hypo-fractionated stereotactic robotic radiotherapy for salvage in adult patients with brainstem glioma , 2013, ecancermedicalscience.
[20] S. Baylin,et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft , 2013, Oncotarget.
[21] C. Brennan,et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine , 2013, Oncotarget.
[22] K. Stegmaier,et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.
[23] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[24] Li Ding,et al. Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.
[25] J. Uhm. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .
[26] M. Souweidane,et al. Proceedings of the diffuse intrinsic pontine glioma (DIPG) Toronto Think Tank: advancing basic and translational research and cooperation in DIPG , 2011, Journal of Neuro-Oncology.
[27] U. Bode,et al. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas , 2011, Expert opinion on biological therapy.
[28] P. Varlet,et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. , 2011, Neuro-oncology.
[29] D. Johnston,et al. A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. , 2010, European journal of cancer.
[30] Amar Gajjar,et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] R. Gilbertson,et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] S. Ferman,et al. Brainstem gliomas— Retrospective analysis of 86 patients , 2009, Journal of the Neurological Sciences.
[33] T. MacDonald,et al. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors , 2009, Pediatric blood & cancer.
[34] Ryung S. Kim,et al. Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases , 2008, Journal of Neuro-Oncology.
[35] T. MacDonald,et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] T. Zhou,et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP‐16: A Children's Oncology Group phase II study , 2008, Pediatric blood & cancer.
[37] T. Zhou,et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high‐grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: A children's oncology group study , 2007, Cancer.
[38] P. Houghton,et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] I. Pollack,et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] I. Pollack,et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. , 2007, Neuro-oncology.
[41] J. Dancey,et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] D. Rating,et al. Treatment of paediatric pontine glioma with oral trophosphamide and etoposide , 2002, British Journal of Cancer.
[43] J J Mazeron,et al. Brainstem gliomas in adults: prognostic factors and classification. , 2001, Brain : a journal of neurology.